KM
NGNE icon

Kalos Management’s Neurogene NGNE Stock Holding History

Kalos Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-728
Closed -$165K – 219
2020
Q1 		$165K Hold
728
– – 0.07% 181
2019
Q4 		$177K Sell
728
-17
-2% -$1.69K 0.06% 187
2019
Q3 		$42K Hold
745
– – 0.02% 194
2019
Q2 		$35K Buy
+745
New +$38.3K 0.02% 189
2019
Q1 		– Sell
-758
Closed -$36K – 163
2018
Q4 		$36K Sell
758
-75
-9% -$3.65K 0.02% 188
2018
Q3 		$46K Buy
833
+40
+5% +$2.36K 0.02% 160
2018
Q2 		$226K Hold
793
– – 0.1% 173
2018
Q1 		$226K Hold
793
– – 0.13% 103
2017
Q4 		$198K Buy
+793
New +$186K 0.09% 193

Other funds holding NGNE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Kalos Management's NGNE Position: Q2 2020 in Review

Kalos Management sold out of Neurogene (NGNE) in Q2 2020, closing a stake of 728 shares — an estimated $165K sold.

Kalos Management first reported a position in NGNE in Q4 2017 and held it in 9 quarters. The position peaked at $226K in Q2 2018. 74 funds tracked by Wall St. Rank hold NGNE as of Q2 2020.

  • Kalos Management reported no remaining Neurogene position as of Q2 2020 after selling out during the quarter.
  • Kalos Management sold 728 Neurogene shares in Q2 2020, an estimated $165K.
  • Kalos Management first reported a position in Neurogene in Q4 2017 and held it in 9 quarters.
  • Kalos Management's Neurogene position peaked at $226K in Q2 2018.
  • 74 funds tracked by Wall St. Rank held Neurogene as of Q2 2020.

Based on Kalos Management's 13F filing for Q2 2020, filed 13 Aug 2020.